Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 15/20 | 0.83 |
| ▸ | MMP1 | P03956 | 3/20 | 0.59 |
| ▸ | FCER2 | P06734 | 3/20 | 0.59 |
| ▸ | F2 | P00734 | 1/20 | 0.53 |
| ▸ | PROC | P04070 | 1/20 | 0.53 |
| ▸ | KLK1 | P06870 | 2/20 | 0.48 |
| ▸ | MME | P08473 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
| ▸ | CPA1 | P15085 | 1/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21669886 | 1.00 | KLKB1 (0.83) | KLKB1MMP1FCER2F2PROC | |
| Trifluoroacetic Acid SCHEMBL15900948 | 0.96 | KLKB1 (0.77) | KLKB1MMP1FCER2F2PROC | |
| SCHEMBL14485877 | 0.94 | KLKB1 (0.82) | KLKB1MMP1FCER2F2PROC | |
| SCHEMBL14485873 | 0.94 | KLKB1 (0.82) | KLKB1MMP1FCER2F2PROC | |
| SCHEMBL14485630 | 0.91 | KLKB1 (1.00) | KLKB1MMP1FCER2KLK1 | |
| SCHEMBL14486255 | 0.90 | KLKB1 (0.76) | KLKB1MMP1FCER2KLK1MME | |
| SCHEMBL15901162 | 0.90 | KLKB1 (0.76) | KLKB1MMP1FCER2KLK1MME | |
| SCHEMBL14485707 | 0.89 | KLKB1 (0.67) | KLKB1MMP1FCER2F2PROC | |
| SCHEMBL14485616 | 0.89 | KLKB1 (0.78) | KLKB1MMP1FCER2KLK1 | |
| SCHEMBL15900904 | 0.89 | KLKB1 (0.78) | KLKB1MMP1FCER2KLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200261383-A1 | PHARMACEUTICAL COMPOSITIONS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2020-08-20 | — | — | US | claimed |
| CN-111032018-A | Pharmaceutical composition | 卡尔维斯塔制药有限公司 | 2020-04-17 | — | — | CN | claimed |
| EP-2729443-B3 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LTD (GB) | 2020-02-12 | — | — | EP | claimed |
| US-10478409-B2 | Pharmaceutical compositions | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2019-11-19 | — | — | US | claimed |
| EP-2943181-B1 | PHARMACEUTICAL COMPOSITIONS | KALVISTA PHARMACEUTICALS LTD (GB) | 2019-04-10 | — | — | EP | claimed |
| US-20180021271-A1 | Pharmaceutical Compositions | KALVISTA PHARMACEUTICALS LTD (GB) | 2018-01-25 | — | — | US | claimed |
| US-9849100-B2 | Pharmaceutical compositions suitable for parenteral administration comprising aqueous suspensions of benzylamine derivatives having low solubilities | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2017-12-26 | — | — | US | claimed |
| CN-103687846-B | Benzyl amine derivative as inhibitors of plasma kallikrein | 卡尔维斯塔制药有限公司 | 2016-06-22 | — | — | CN | claimed |
| US-9234000-B2 | Benzylamine derivatives as inhibitors of plasma kallikrein | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2016-01-12 | — | — | US | claimed |
| US-20150342910-A1 | PHARMACEUTICAL COMPOSITIONS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2015-12-03 | — | — | US | claimed |
| EP-2729443-B1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LTD (GB) | 2015-11-25 | — | — | EP | claimed |
| US-20150225450-A1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LTD (GB) | 2015-08-13 | — | — | US | claimed |
| US-9051249-B2 | Benzylamine derivatives as inhibitors of plasma kallikrein | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2015-06-09 | — | — | US | claimed |
| US-20140213611-A1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2014-07-31 | — | — | US | claimed |
| EP-2729443-A1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | Kalvista Pharmaceuticals Limited (GB) | 2014-05-14 | — | — | EP | claimed |
| WO-2013005045-A1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2013-01-10 | — | — | WO | claimed |
| US-20200261383-A1 | PHARMACEUTICAL COMPOSITIONS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2020-08-20 | — | — | US | disclosed |
| CN-111032018-A | Pharmaceutical composition | 卡尔维斯塔制药有限公司 | 2020-04-17 | — | — | CN | disclosed |
| WO-2013005045-A1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2013-01-10 | — | — | WO | disclosed |
| WO-2013005045-A1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2013-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150342910-A1 | PHARMACEUTICAL COMPOSITIONS | PDE6D, ABCC9, RAB29 | KLKB1 2921/4885MMP1 1240/4885FCER2 2604/4885 |
| US-20200261383-A1 | PHARMACEUTICAL COMPOSITIONS | ADCY9, PDE6D, PDE6G | KLKB1 4010/4885MMP1 2255/4885FCER2 3444/4885 |
| US-20180021271-A1 | Pharmaceutical Compositions | PDE6D, ABCC9, PDE6H | KLKB1 2771/4885MMP1 2077/4885FCER2 2033/4885 |
| US-20150225450-A1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK1, BDKRB1 | KLKB1 1/4885MMP1 256/4885FCER2 1318/4885 |
| US-10478409-B2 | Pharmaceutical compositions | PDE6D, ABCC9, PDE6H | KLKB1 2771/4885MMP1 2077/4885FCER2 2033/4885 |
| US-20140213611-A1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK1, BDKRB1 | KLKB1 1/4885MMP1 256/4885FCER2 1318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.